Diagnos (TSE:ADK)
:ADK
Want to see TSE:ADK full AI Analyst Report?
ADK Stock Chart & Stats
C$0.36
C$0.03(9.38%)
At close: 4:00 PM EST
C$0.36
C$0.03(9.38%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.42
Previous CloseN/A
Volume270.50K
Average Volume (3M)342.67K
Market Cap
C$22.88M
Enterprise ValueC$25.03M
Total Cash (Recent Filing)C$3.40M
Total Debt (Recent Filing)C$2.00M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)43.19
Price to Sales (P/S)453.09
P/FCF Ratio-7.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI Retinal Screening Platform (CARA)Diagnos' CARA platform is a specialized AI/image-analysis product focused on retinal disease screening. A validated clinical platform targeting diabetic retinopathy creates durable product differentiation, higher switching costs, and the potential for sustained adoption within organized screening workflows.
Revenue Model Aligned With Screening ProgramsSelling access to an AI screening service via organized programs supports recurring, usage-linked revenue as screening volumes grow. This model can produce predictable cash flows from contracts and scale with program adoption, strengthening long-term commercial durability if contracts are retained.
Positive Equity And Tangible Asset BaseReturning to positive equity and holding tangible assets provides a more stable solvency footing than prior years of negative equity. This improvement increases the company's ability to secure financing or partnerships and reduces immediate insolvency risk, giving time to execute commercialization efforts.
Bears Say
Persistent Negative Operating Cash FlowChronic negative operating cash flow signals the business consumes cash to operate and cannot self-fund growth or working capital. Over months this forces reliance on external financing, increases dilution or debt risk, and constrains investment into sales, regulatory clearance, or product improvements.
Fragile Balance Sheet With High LeverageDebt around twice reported equity limits financial flexibility and raises refinancing and covenant risk. For a small, loss-making medtech, elevated leverage reduces runway, increases interest burden, and makes the company vulnerable to revenue shortfalls or adverse financing market conditions.
Steep Revenue Decline And Widening LossesSharp revenue contraction while losses widen undermines unit economics and scalability of the CARA platform. Declining scale increases per-unit costs, weakens negotiating leverage with customers, and lengthens the path to breakeven absent material new contracts or cost restructuring.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.17 and its highest was C$0.41 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$22.88M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Aug 20, 2026 which is in 68 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Jun 11, 2026. The company reported -C$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.01.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Diagnos
DIAGNOS Inc. is a technology firm that delivers software-based services across a broad international footprint, encompassing Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. A significant portion of its operations focuses on healthcare, where it provides Computer Assisted Retina Analysis (CARA). This advanced web-based platform is designed to support medical professionals in the early detection of diabetic retinopathy. It also empowers eye care specialists by enabling clear visualization of both standard retinal features and any pathological changes. Beyond its healthcare offerings, DIAGNOS Inc. extends its expertise through consulting services, specializing in the fields of data analytics and artificial intelligence (AI). Established in 1998, the company maintains its corporate headquarters in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---